Heyu-B announced that China's State Drug Administration has approved ABSK211's new drug clinical trial application. ABSK211 is an oral, high-potency, small-molecule Pan-KRAS inhibitor. It has broad-spectrum activity against various KRAS gene changes and is used to treat advanced solid tumor patients with KRAS gene changes. Previously, ABSK211 received IND approval from the US Food and Drug Administration on July 8. The receipt of IND approval in both China and the US is a key milestone in ABSK211's global clinical development plan.

Heyu-B announced that China's State Drug Administration has approved ABSK211's new drug clinical trial application. ABSK211 is an oral, high-potency, small-molecule Pan-KRAS inhibitor. It has broad-spectrum activity against various KRAS gene changes and is used to treat advanced solid tumor patients with KRAS gene changes. Previously, ABSK211 received IND approval from the US Food and Drug Administration on July 8. The receipt of IND approval in both China and the US is a key milestone in ABSK211's global clinical development plan.